<DOC>
	<DOC>NCT01604889</DOC>
	<brief_summary>The study design includes an open-label, dose escalation phase followed by a blinded, randomized phase, which combines INCB024360 (an oral IDO1 inhibitor) with an approved therapy and compares to approved therapy plus placebo in metastatic melanoma patients.</brief_summary>
	<brief_title>A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or female subjects, aged 18 years or older with unresectable or metastatic melanoma. A life expectancy of &gt;12 weeks. Laboratory ranges and medical criteria met, as defined within the protocol. Subject may have received more than 1 prior regimen of systematic treatment for unresectable or metastatic melanoma. For Phase 2 period of the study only, Subjects must have archival tumor tissue available and collected with the prior 6 months or accessible disease for pretreatment, study biopsy. Pregnant or nursing women. Current investigational trial participation with another investigational product or subjects who have received any anticancer medications within 21 days prior to screening (6 weeks for mitomycinC or nitrosoureas.) Subjects receiving monoamine oxidase inhibitors (MAOI)s; subjects who have ever had Serotonin Syndrome after receiving one or more serotonergic drugs. Subjects who have received prior immune checkpoint inhibitors (eg antiCTLA4, antiPD1, anti PDL1 and others) who have had Grade 3 or 4 hepatotoxicity, immune colitis requiring infliximab, endocrine toxicity not controlled by replacement, any other Grade 4 immune adverse events (AEs) or ocular toxicity Subjects with protocolspecified active autoimmune process except vitiligo or thyroiditis. Subjects with concurrent conditions that would jeopardize the safety of the safety of the subject or compliance with the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Melanoma, Skin Cancer, Oncology</keyword>
</DOC>